title: [Clinical efficiency of combined therapy using adaptol for atopic dermatitis].
abstract: OBJECTIVE
  To study the effect of the daytime anxiolytic adaptol on the efficiency and tolerability of combination treatment for atopic dermatitis (AD).
  
  
  METHODS
  Eighty patients with different clinical forms of AD were examined and then divided into 2 identical groups. The patients' mean age was 30.7 +/- 11.2 years; the mean disease duration was 20.2 +/- 12.8 years. Group 1 patients (n = 40) received standard treatment involving disintoxication therapy, prednisolone 30-60 mg/day, antihistamines, phototherapy (20 sessions), topical steroids and topical emollients. Group 2 patients (n = 40) took additionally adaptol as 3 tablets (1500 mg) daily. The efficiency of therapeutic measures was evaluated in 2 steps: by taking into account the changes in the scoring atopic dermatitis index (SCORAD) and the Dermatology Life Quality Index (DLQI) scores 4 weeks following the initiation of treatment and once more after 12 weeks.
  
  
  RESULTS
  There was a tendency for the more pronounced decrease in SCORAD scores in Group 2 (using adaptol) versus Group 1 (standard treatment) to 9.8 +/- 2.57 and 10.8+ +/- 2.64, respectively. There were drops in SCORAD scores by 4.1 and 3.6 times, respectively. Twelve weeks after 12 weeks of treatment initiation was 7.1 +/- 2.13 scores in the adaptol group; on the contrary, this indicator increased slightly due to evolving recurrences and amounted to as many as 11.9 +/- 2.41 scores on the average. In Group 1, DLQI improved by 73% following 4 weeks and decreased by 1% after 12 weeks while in Group 2, it improved by 81% following 4 weeks and continued to improve up to 85% after 12 weeks.
  
  
  CONCLUSIONS
  Comparison of examined dermatology indices in AD patients receiving standard treatment and treatment including adaptol gives proof to the great value and efficiency of using adaptol during an exacerbation and in the postrecurrence period.
authors.forename: E V
authors.initials: EV
authors.lastname: Orlov
authors.forename: P E
authors.initials: PE
authors.lastname: Konnov
authors.forename: A A
authors.initials: AA
authors.lastname: Arsen'eva
mesh_terms: D000328:Adult; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000009:adverse effects; D001736:Biureas / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D003876:Dermatitis, Atopic / Q000175:diagnosis / Q000503:physiopathology / Q000523:psychology / Q000628:therapy*; D004333:Drug Administration Routes; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006633:Histamine Antagonists / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010789:Phototherapy / Q000379:methods*; D011788:Quality of Life; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D014151:Anti-Anxiety Agents; D001736:Biureas; D005938:Glucocorticoids; D006633:Histamine Antagonists; C015979:mebikar